Cost-Effectiveness of Two Testing Strategies for BRCA Mutations in Ovarian Cancer
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer. “In 2020 ASCO recommended that all women with epithelial ovarian cancer have germline testing for BRCA1/2 mutations, and those without a germline pathogenic variant should have somatic tumor testing, to determine eligibility for PARP inhibitor therapy,” wrote Janice S. Kwon, University of British Columbia, Vancouver, BC, Canada, and colleagues. “An alternate strategy is to start with tumor testing first, and to conduct germline testing only in those with a pathogenic variant in the tumor, or a significant family history,” they continued.